AAM
ANIP icon

Advisors Asset Management’s ANI Pharmaceuticals ANIP Stock Holding History

Advisors Asset Management’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$34.7K Sell
419
-528
-56% -$42.4K ﹤0.01% 1324
2026
Q1 		$72.8K Sell
947
-47
-5% -$3.67K ﹤0.01% 1268
2025
Q4 		$78.5K Sell
994
-11
-1% -$952 ﹤0.01% 1263
2025
Q3 		$92.1K Buy
1,005
+100
+11% +$8.15K ﹤0.01% 1222
2025
Q2 		$59.1K Buy
905
+480
+113% +$31.3K ﹤0.01% 1270
2025
Q1 		$28.5K Buy
+425
New +$25.4K ﹤0.01% 1330
2020
Q4 		– Sell
-210
Closed -$5.92K – 1512
2020
Q3 		$5.92K Sell
210
-306
-59% -$9.11K ﹤0.01% 1498
2020
Q2 		$16.7K Sell
516
-14
-3% -$502 ﹤0.01% 1475
2020
Q1 		$21.6K Sell
530
-55
-9% -$2.92K ﹤0.01% 1383
2019
Q4 		$36.1K Buy
585
+28
+5% +$1.85K ﹤0.01% 1426
2019
Q3 		$40.6K Buy
557
+235
+73% +$17.6K ﹤0.01% 1416
2019
Q2 		$26.5K Buy
+322
New +$22.9K ﹤0.01% 1446

Other funds holding ANIP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
GACM
Global Alpha Capital Management Montreal, Quebec, Canada $1.67B AUM 35.09% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Advisors Asset Management's ANIP Position: Q2 2026 in Review

Advisors Asset Management reduced its ANI Pharmaceuticals (ANIP) stake by 56% in Q2 2026, selling an estimated $42.4K and leaving 419 shares worth $34.7K. The position accounts for ﹤0.01% of the portfolio, ranked #1324.

Advisors Asset Management first reported a position in ANIP in Q2 2019 and has held it in 12 quarters since. The position peaked at $92.1K in Q3 2025. 307 funds tracked by Wall St. Rank hold ANIP as of Q2 2026.

  • Advisors Asset Management held 419 shares of ANI Pharmaceuticals worth $34.7K as of Q2 2026.
  • Advisors Asset Management sold 528 ANI Pharmaceuticals shares in Q2 2026, an estimated $42.4K.
  • ANI Pharmaceuticals made up ﹤0.01% of Advisors Asset Management's portfolio in Q2 2026, its #1324 holding.
  • Advisors Asset Management first reported a position in ANI Pharmaceuticals in Q2 2019 and has held it in 12 quarters since.
  • Advisors Asset Management's ANI Pharmaceuticals position peaked at $92.1K in Q3 2025.
  • 307 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q2 2026.

Based on Advisors Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.